Skip to main content

and
  1. Article

    Open Access

    The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification

    K. Nachtkamp, C. Strupp, M. Vukelja, A. Kasprzak, D. Haase, C. Ganster in Leukemia (2024)

  2. Article

    Open Access

    Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

    In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic...

    A. Kuendgen, M. Nomdedeu, H. Tuechler, G. Garcia-Manero, R. S. Komrokji in Leukemia (2021)

  3. No Access

    Article

    Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)

    A risk-adapted treatment strategy is mandatory for myelodysplastic syndromes (MDS). We refined the World Health Organization (WHO)-classification-based Prognostic Scoring System (WPSS) by determining the impac...

    M G Della Porta, H Tuechler, L Malcovati, J Schanz, G Sanz, G Garcia-Manero in Leukemia (2015)

  4. No Access

    Article

    Monosomal karyotype in MDS: explaining the poor prognosis?

    Monosomal karyotype (MK) is associated with an adverse prognosis in patients in acute myeloid leukemia (AML). This study analyzes the prognostic impact of MK in a cohort of primary, untreated patients with mye...

    J Schanz, H Tüchler, F Solé, M Mallo, E Luño, J Cervera, J Grau, B Hildebrandt in Leukemia (2013)

  5. No Access

    Article

    Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

    Myelodysplastic syndromes (MDS) with del(5q) are considered to have a benign course of the disease. In order to address the issue of the propensity of those patients to progress to acute myeloid leukemia (AML)...

    U Germing, M Lauseker, B Hildebrandt, A Symeonidis, J Cermak, P Fenaux in Leukemia (2012)

  6. No Access

    Article

    Myelodysplastic Syndromes (MDS) – News from ASH 2010

    In previous years ASH presentations regarding MDS focused on clinical trials in order to establish tailored treatment options for a significant number of patients. In contrast the main topics of the recent mee...

    T. Nösslinger, M. Pfeilstöcker in memo - Magazine of European Medical Oncology (2011)

  7. No Access

    Article

    Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q

    This cooperative study assessed prognostic factors for overall survival (OS) and risk of transformation to acute myeloid leukemia (AML) in 541 patients with de novo myelodysplastic syndrome (MDS) and deletion 5q....

    M Mallo, J Cervera, J Schanz, E Such, G García-Manero, E Luño, C Steidl in Leukemia (2011)

  8. No Access

    Article

    Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)

    The international prognostic scoring system (IPSS) is considered the gold standard for risk assessment in primary myelodysplastic syndromes (MDS). This score includes several prognostic factors except serum la...

    U Germing, B Hildebrandt, M Pfeilstöcker, T Nösslinger, P Valent, C Fonatsch in Leukemia (2005)

  9. No Access

    Article

    Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma

    Molecular and genetic events associated with the transition from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) are still poorly characterized. We investigated serial bone m...

    H Kaufmann, J Ackermann, C Baldia, T Nösslinger, R Wieser, S Seidl, V Sagaster in Leukemia (2004)

  10. No Access

    Article

    In vivo and in vitro effects of cytokines and the hemoregulatory peptide dimer (pEEDCK)2 (pyroGlu-Glu-Asp-Cys-Lys)2 on Gα16-positive hematopoiesis

    G proteins play an important role in signal transduction from cytokine receptors to intracellular effectors via different pathways, eg involving tyrosine kinases. In our previous studies, we demonstrated that ...

    M Pfeilstöcker, H Karlic, J Paukovits, G Anzenberger, N Louda, J Salamon in Leukemia (1999)